Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO-A-HAM in Primary Refractory AML
NCT00143975Phase 2Completed
- Sponsor
- Ulm University
- Start
- Jun 2004
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Ulm University. Primary endpoint: Complete Remission Rate at day 30. Started Jun 2004; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00143975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143975.